Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905464 | 1.00 | ADORA1 (0.72) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2835895 | 0.91 | METTL3 (0.65) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2835899 | 0.91 | METTL3 (0.65) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL6907702 | 0.90 | METTL3 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL6902192 | 0.89 | ADORA1 (0.62) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL9387983 | 0.89 | ADORA1 (0.66) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8744184 | 0.88 | ADORA1 (0.66) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL6900365 | 0.88 | ADORA1 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL9491623 | 0.88 | ADORA1 (0.67) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2235451 | 0.87 | GSK3A (0.67) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| EP-1424064-B1 | Use of adenosin or an adenosin analog to smooth out fine lines | OREAL (FR) | 2007-06-06 | — | — | EP | claimed |
| WO-2007042679-A2 | COSMETIC COMPOSITION CONTAINING A NON-PHOSPHATE COMPOUND BASED ON ADENOSINE AND A TIGHTENING POLYMER | L'OREAL (FR) | 2007-04-19 | — | — | WO | claimed |
| US-20040146474-A1 | Method for softening lines and relaxing the skin with adenosine and adenosine analogues | L'OREAL (FR) | 2004-07-29 | — | — | US | claimed |
| EP-1424064-A1 | Use of adenosin or an adenosin analog to smooth out fine lines | L'OREAL (FR) | 2004-06-02 | — | — | EP | claimed |
| US-6316423-B1 | ANTIISCHEMIC AGENT, HYPOXIA AND ANOXIA BRAIN DAMAGE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMANT OF HEALTH AND HUMAN SERVICES | 2001-11-13 | — | — | US | claimed |
| EP-0167567-A1 | TREATMENT OF METASTASIS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1986-01-15 | — | — | EP | claimed |
| WO-1985002616-A1 | TREATMENT OF METASTASIS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1985-06-20 | — | — | WO | claimed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20210251901-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200316101-A1 | APPLICATIONS OF TRIACETYL-3-HYDROXYL PHENYL ADENOSINE IN TREATING VASCULAR INFLAMMATIONS OR IMPROVING VASCULAR ENDOTHELIUM FUNCTIONS | Beijing Gushen Life Health Technology Co., Ltd. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20200121603-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-2906547-B1 | COSMETIC COMPOSITIONS CONTAINING AT LEAST ONE HYDROTROPE AND AT LEAST ONE ACTIVE COMPOUND | OREAL (FR) | 2019-11-20 | — | — | EP | disclosed |
| EP-3466433-A1 | APPLICATIONS OF TRIACETYL-3-HYDROXYL PHENYL ADENOSINE IN TREATING VASCULAR INFLAMMATIONS OR IMPROVING VASCULAR ENDOTHELIUM FUNCTIONS | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| US-6258836-B1 | FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER | PROTARGA, INC. | 2001-07-10 | — | — | US | disclosed |
| US-6255292-B1 | INCREASING CELLULAR CONTRACTIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-07-03 | — | — | US | disclosed |
| WO-2000024365-A1 | TREATMENT OF SKIN WITH ADENOSINE OR ADENOSINE ANALOG | UNIVERSITY OF MASSACHUSETTS (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1996029345-A1 | NOVEL INOTROPIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0708781-A1 | A 3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002604-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316101-A1 | APPLICATIONS OF TRIACETYL-3-HYDROXYL PHENYL ADENOSINE IN TREATING VASCULAR INFLAMMATIONS OR IMPROVING VASCULAR ENDOTHELIUM FUNCTIONS | ADORA2A, LIPG, VCAM1 | ADORA1 18/4885SMN1; SMN2 4691/4885ADORA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.